Tamsulosin Hydrochloride
Product Images NDC 55648-516

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 55648-516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 Tablets Container Label (Tamsulosin HCl Capsules Container Label 100 Tablets)

Label for Tamsulosin Hydrochloride Capsules, USP 0.4 mg, containing 100 capsules. The label includes the NDC 64679-516-02, indicates the product is prescription-only, and is manufactured by Wockhardt Limited in Mumbai, India. Storage instructions specify 20°C to 25°C. Distributor information for Wockhardt USA LLC in Parsippany, NJ, is also provided. The label features a barcode and the Wockhardt logo.*

FDA Label Image

Figure1 (Tamsulosin HCl Capsules Figure 1)

A plasma concentration versus time graph showing Tamsulosin Hydrochloride levels over 36 hours in fasted and fed states. The graph displays higher peak plasma concentration when fasted, with both curves declining over time.*

FDA Label Image

Figure 2a (Tamsulosin HCl Capsules Figure 2a)

A line graph showing mean change over duration of treatment in weeks for TAMSULOSIN HYDROCHLORIDE at 0.8 mg and 0.4 mg doses compared to placebo. The x-axis represents treatment duration from baseline to 13 weeks plus LOCF, while the y-axis shows mean change. Three lines depict the treatments: 0.8 mg with circles, 0.4 mg with triangles, and placebo with squares.*

FDA Label Image

Figure 2b (Tamsulosin HCl Capsules Figure 2b)

A line graph showing mean change over time by duration of treatment in weeks for Tamsulosin Hydrochloride at doses 0.3 mg and 0.4 mg compared to placebo. The x-axis represents the treatment duration from 0 to 13 weeks plus last observation carried forward (LOCF), and the y-axis shows mean change from 0 to -11. Three lines depict outcomes for 0.3 mg (circles), 0.4 mg (triangles), and placebo (squares), illustrating a greater mean change for the active doses compared to placebo over the treatment period.*

FDA Label Image

Figure3a (Tamsulosin HCl Capsules Figure 3a)

A line graph depicting the mean change in mL/sec over the duration of treatment in weeks, comparing Tamsulosin Hydrochloride doses of 0.8 mg and 0.4 mg versus placebo. The x-axis shows weeks of treatment up to 13 weeks plus LOCF, and the y-axis shows mean change values from 0.0 to 3.0 mL/sec. The graph includes sample sizes per time point and indicates treatment and placebo groups with distinct symbols and lines.*

FDA Label Image

Figure3b (Tamsulosin HCl Capsules Figure 3b)

A line graph showing mean changes in mL/sec over treatment duration in weeks for TAMSULOSIN HYDROCHLORIDE doses of 0.8 mg, 0.4 mg, and placebo. The x-axis represents treatment duration from 0 to 13 weeks and LOCF, with sample sizes noted below. The y-axis shows mean change values up to 3. Treatment groups are differentiated by symbols and line styles.*

FDA Label Image

Structure (Tamsulosin HCl Capsules Structure)

Chemical structure diagram of tamsulosin hydrochloride showing its aromatic rings, sulfonamide group, methoxy and ethoxy substituents, and hydrochloride component, consistent with the active ingredient tamsulosin hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.